オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; dichloromethane; sodium starch glycollate type a; isopropyl alcohol; magnesium stearate; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmaclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmaclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmaclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg); amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; dichloromethane; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmacor moxclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmacor moxclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmacor moxclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.c

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; dichloromethane; sodium starch glycollate type a; magnesium stearate; isopropyl alcohol; colloidal anhydrous silica; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmaclav tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmaclav tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmaclav tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: isopropyl alcohol; magnesium stearate; dichloromethane; colloidal anhydrous silica; sodium starch glycollate type a; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmacor clavam tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmacor clavam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmacor clavam tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - amoxicillin trihydrate, quantity: 1012.617 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149.774 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; dichloromethane; magnesium stearate; sodium starch glycollate type a; colloidal anhydrous silica; isopropyl alcohol; titanium dioxide; hypromellose; purified talc; diethyl phthalate; ethylcellulose - pharmacor clavam tablets are indicated for short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology):,urinary tract infections (uncomplicated and complicated), lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis, upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis.skin and skin structure infection.,appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to pharmacor clavam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed above, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate.,the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to pharmacor clavam tablets should not require the addition of another antibiotic due to the amoxycillin content of these products.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 35.125 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; hypromellose; magnesium stearate; calcium hydrogen phosphate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 25 mg tablets is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 140.5 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: hypromellose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 100 mg tablets is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 140.5 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; croscarmellose sodium; hypromellose; magnesium stearate; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 100 mg tablets is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 70.25 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; hypromellose; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 50 mg tablets is not indicated for use by women.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - sildenafil citrate, quantity: 70.25 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; lactose monohydrate; triacetin; indigo carmine aluminium lake - indicated for the treatment of erectile dysfunction in adult males. sildenafil citrate 50 mg tablets is not indicated for use by women.